Top

Published in:

01-12-2012 | Research Article

Different effects of ERβ and TROP2 expression in Chinese patients with early-stage colon cancer

Authors: Yu-Jing Fang, Guo-Qiang Wang, Zhen-Hai Lu, Lin Zhang, Ji-Bin Li, Xiao-Jun Wu, Pei-Rong Ding, Qing-Jian Ou, Mei-Fang Zhang, Wu Jiang, Zhi-Zhong Pan, De-Sen Wan

Published in: Tumor Biology | Issue 6/2012

Abstract

Estrogen receptor beta (ERβ) and TROP2 expressed in colon carcinoma and might play an important role there. We explored the relationship of ERβ and TROP2 expression with the prognosis of early-stage colon cancer. ERβ and TROP2 levels were assessed by immunohistochemistry in normal mucosa and tumoral tissues from 220 Chinese patients with T₃N₀M₀ (stage IIa) and T₄N₀M₀ (stage IIb) colon cancer in the Cancer Center, Sun Yat-sen University, who underwent curative surgical resection between 1995 and 2003. The Cox proportional hazards regression model was applied to analyze the overall survival (OS) data, and the ROC curve, Kaplan–Meier estimate, log rank test, and Jackknife method were used to show the effect of ERβ and TROP2 expression at different stages of cancer. The 5-year survival rates were not significantly different between the patients with stage IIa and stage IIb colon cancer (83 vs. 80 %, respectively). The high expression of ERβ was related to decreasing OS in stage IIa and stage IIb colon cancer, while the high expression of TROP2 was related to decreasing OS in stage IIb colon cancer. The expression of ERβ and TROP2 has tumor-suppressive and tumor-promoting effect in stage IIa and stage IIb colon cancer, respectively.

Honma N, Saji S, Kurabayashi R, Aida J, Arai T, Horii R, et al. Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. APMIS. 2008;116:923–30.PubMedCrossRef

Batistatou A, Kyzas PA, Goussia A, Arkoumani E, Voulgaris S, Polyzoidis K, et al. Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours. J Neurooncol. 2006;77:17–23.PubMedCrossRef

Nose N, Sugio K, Oyama T, Nozoe T, Uramoto H, Iwata T, et al. Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung. J Clin Oncol. 2009;27:411–7.PubMedCrossRef

Witte D, Chirala M, Younes A, Li Y, Younes M. Estrogen receptor beta is expressed in human colorectal adenocarcinoma. Hum Pathol. 2001;32:940–4.PubMedCrossRef

Fang YJ, Lu ZH, Wang F, Wu XJ, Li LR, Zhang LY, et al. Prognostic impact of ERbeta and MMP7 expression on overall survival in colon cancer. Tumor Biol. 2010;31:651–8.CrossRef

Liu L, Chirala M, Younes M. Expression of estrogen receptor-beta isoforms in Barrett's metaplasia, dysplasia and esophageal adenocarcinoma. Anticancer Res. 2004;24:2919–24.PubMed

Matsuyama S, Ohkura Y, Eguchi H, Kobayashi Y, Akagi K, Uchida K, et al. Estrogen receptor beta is expressed in human stomach adenocarcinoma. J Cancer Res Clin Oncol. 2002;128:319–24.PubMedCrossRef

Abe K, Miki Y, Ono K, Mori M, Kakinuma H, Kou Y, et al. Highly concordant coexpression of aromatase and estrogen receptor beta in non-small cell lung cancer. Hum Pathol. 2010;41:190–8.PubMedCrossRef

Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, et al. Metastases of prostate cancer express estrogen receptor-beta. Urology. 2004;64:814–20.PubMedCrossRef

10.

Pais V, Leav I, Lau KM, Jiang Z, Ho SM. Estrogen receptor-beta expression in human testicular germ cell tumors. Clin Cancer Res. 2003;9:4475–82.PubMed

11.

Iwao K, Miyoshi Y, Ooka M, Ishikawa O, Ohigashi H, Kasugai T, et al. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in human pancreatic cancers by real-time polymerase chain reaction. Cancer Lett. 2001;170:91–7.PubMedCrossRef

12.

Deyrup AT, Tretiakova M, Khramtsov A, Montag AG. Estrogen receptor beta expression in vascular neoplasia: an analysis of 53 benign and malignant cases. Mod Pathol. 2004;17:1372–7.PubMedCrossRef

13.

Birkenkamp-Demtroder K, Olesen SH, Sørensen FB, Laurberg S, Laiho P, Aaltonen LA, et al. Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut. 2005;54:374–84.PubMedCrossRef

14.

Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;112:1029–35.PubMedCrossRef

15.

Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer. 2004;112:14–25.PubMedCrossRef

16.

Wang J, Day R, Dong Y, Weintraub SJ, Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther. 2008;7:280–5.PubMedCrossRef

17.

Cubas R, Li M, Chen C, Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009;1796:309–14.PubMed

18.

Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2008;21:186–91.PubMed

19.

Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, et al. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer. 2008;99:1290–5.PubMedCrossRef

20.

Mühlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, et al. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol. 2009;62:152–8.PubMedCrossRef

21.

Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, et al. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Color Dis. 2009;24:875–84.CrossRef

22.

Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res. 2006;12:3057–63.PubMedCrossRef

23.

Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, et al. Gene expression predictors of breast cancer outcomes. Lancet. 2003;361:1590–6.PubMedCrossRef

24.

Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, et al. Oestrogen receptor beta (ERβ) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer. 2003;39:1251–8.PubMedCrossRef

25.

Jassam N, Bell SM, Speirs V, Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncol Rep. 2005;14:17–21.PubMed

26.

Wong NACS, Malcomson RDG, Jodrell DI, Groome NP, Harrison DJ, Saunders PTK. ER beta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates. J Pathol. 2005;207:53–60.PubMedCrossRef

27.

Sumi K, Matsuyama S, Kitajima Y, Miyazaki K. Loss of estrogen receptor B expression at cancer front correlates with tumor progression and poor prognosis of gallbladder cancer. Oncol Rep. 2004;12:979–84.PubMed

28.

Wada-Hiraike O, Imamov O, Hiraike H, Hultenby K, Schwend T, Omoto Y, et al. Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci U S A. 2006;103:2959–64.PubMedCrossRef

29.

Barone M, Scavo MP, Papagni S, Piscitelli D, Guido R, Di Lena M, et al. ER beta expression in normal, adenomatous and carcinomatous tissues of patients with familial adenomatous polyposis. Scand J Gastroenterol. 2010;45:1320–8.PubMedCrossRef

30.

Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res. 2007;67:2366–72.PubMedCrossRef

31.

Martineti V, Picariello L, Tognarini I, Sala SC, Gozzini A, Azzari C, et al. ER beta is a potent inhibitor of cell proliferation in the HCT8 human colon cancer cell line through regulation of cell cycle components. Endocr Relat Cancer. 2005;12:455–69.PubMedCrossRef

32.

Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253.PubMedCrossRef

Title: Different effects of ERβ and TROP2 expression in Chinese patients with early-stage colon cancer
Authors: Yu-Jing Fang
Guo-Qiang Wang
Zhen-Hai Lu
Lin Zhang
Ji-Bin Li
Xiao-Jun Wu
Pei-Rong Ding
Qing-Jian Ou
Mei-Fang Zhang
Wu Jiang
Zhi-Zhong Pan
De-Sen Wan
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0484-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Effects of salinomycin on human ovarian cancer cell line OV2008 are associated with modulating p38 MAPK

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy

ING4 is negatively correlated with microvessel density in colon cancer

Characterization of DNA hypermethylation in two cases of peritoneal mesothelioma

Loss of expression of the differentially expressed in adenocarcinoma of the lung (DAL-1) protein is associated with metastasis of non-small cell lung carcinoma cells

Aberrant SERCA3 expression is closely linked to pathogenesis, invasion, metastasis, and prognosis of gastric carcinomas

Keynote webinar | Spotlight on antibody–drug conjugates in cancer